NVIDIA — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVLilly Asia Ventures+2 more
Databricks provides a unified platform for data engineering, analytics, and artificial intelligence, enabling organizations to build and deploy data and AI applications on cloud infrastructure.
AI & Machine LearningCloud ComputingData & InfrastructureEnterprise SoftwareSan Francisco, US
Ali Ghodsi(Co-founder & CEO)inIon Stoica(Executive Officer, Director, Promoter)Matei Zaharia(Executive Officer, Director, Promoter)inReynold Xin(Founder)inPatrick Wendell(Founder)inAndy Konwinski(Founder)in
Co-investors137 VenturesA.Capital VenturesAglae VenturesAlkeon InnovationAltra VentureAmplify Partners+70 more
Inflection builds AI models that combine emotional and raw intelligence to create trustworthy AI agents for individuals and enterprises.
AI & Machine LearningEnterprise SoftwarePalo Alto, US
Reid Hoffman(Co-Founder)inMustafa Suleyman(Co-founder & CEO)inKarén Simonyan(Co-Founder & former Chief Scientist)Sean White(Chief Executive Officer)inVibhu Mittal(Chief Technology Officer)Ted Shelton(Chief Operating Officer)
Co-investorsChamaeleonCoreWeaveEric SchmidtGeneral PartnershipGreylock PartnersHorizons Ventures+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.